Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Study of Nab-paclitaxel for Neoadjuvant Breast Cancer
NCT03959397Phase 2Unknown
- Sponsor
- Jilin University
- Start
- Jun 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in breast cancer, sponsored by Jilin University. Primary endpoints: Pathological Complete Remission at 2 weeks and Disease-Free Survival at 6 months. Status: unknown.
02
Drugs
paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03959397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03959397.